Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425419 | 0.91 | NFE2L2 (0.42) | AHREPAS1NFE2L2 | |
| SCHEMBL26425427 | 0.88 | ALDH1A1 (0.41) | EPAS1ALDH1A1 | |
| SCHEMBL26425423 | 0.86 | CYP1A1 (0.42) | EPAS1ALDH1A1PPARGNFE2L2 | |
| SCHEMBL26426007 | 0.84 | PTGS1 (0.47) | AHRNFE2L2 | |
| SCHEMBL28960351 | 0.84 | PTGS1 (0.37) | AHREPAS1ALDH1A1NFE2L2 | |
| SCHEMBL26425434 | 0.84 | NFE2L2 (0.40) | ALDH1A1PPARGNFE2L2 | |
| SCHEMBL26426000 | 0.84 | PTGS1 (0.37) | AHREPAS1ALDH1A1NFE2L2 | |
| SCHEMBL24254424 | 0.84 | MAPT (0.39) | EPAS1ALDH1A1 | |
| SCHEMBL4608215 | 0.83 | EPAS1 (0.45) | EPAS1ALDH1A1ADORA2AADORA1 | |
| SCHEMBL28442823 | 0.83 | AHR (0.42) | AHREPAS1NR1H2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | AHR 3843/4885EPAS1 2716/4885NR1H2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.